论文部分内容阅读
目的:观察西格列汀联合阿卡波糖治疗2型糖尿病的疗效及安全性。方法:70例2型糖尿病患者随机分为两组各35例。观察组予西格列汀联合阿卡波糖,对照组予西格列汀联合格列美脲,治疗24周。比较两组患者治疗前后空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbAlc)、体重指数(BMI)水平变化,以及低血糖事件发生率。结果:治疗后,两组FBG、2hPG、HbAlc均较治疗前明显下降(P<0.05),两组比较,差异无统计学意义(P>0.05)。治疗后,两组BMI比较,差异有统计学意义(P<0.05)。观察组发生低血糖人数低于对照组(P<0.05)。结论:西格列汀联合阿卡波糖治疗2型糖尿病,可有效降低患者血糖,体重指数下降明显,发生低血糖的风险低,安全性好。
Objective: To observe the efficacy and safety of sitagliptin plus acarbose in type 2 diabetes mellitus. Methods: Seventy patients with type 2 diabetes were randomly divided into two groups of 35 cases. The observation group was given sitagliptin combined with acarbose, while the control group was treated with sitagliptin and glimepiride for 24 weeks. The changes of fasting blood glucose (FBG), 2h postprandial blood glucose (2hPG), HbAlc, body mass index (BMI) and incidence of hypoglycaemia were compared between the two groups before and after treatment. Results: After treatment, FBG, 2hPG and HbAlc in both groups were significantly lower than those before treatment (P <0.05). There was no significant difference between the two groups (P> 0.05). After treatment, the difference between the two groups was statistically significant (P <0.05). The incidence of hypoglycemia in observation group was lower than that in control group (P <0.05). Conclusion: The combination of sitagliptin and acarbose in the treatment of type 2 diabetes mellitus can effectively reduce the blood sugar, body mass index decreased significantly, the risk of hypoglycemia is low, and the safety is good.